Tag Archives: Venture Capital

Our investment in Lime: Maximising micro-mobility

Atomico

Today, we’re delighted to announce our investment in Lime. Led by co-founders Brad Bao and Toby Sun, Lime is an organisation driving behavioural change at mass scale and lightning speed.

We set out to back founders who can address the world’s biggest challenges, and improve the way we live. Moving more people more frequently, decongesting cities, and improving air quality for those who live there, are certainly monumental challenges. Lime’s e-bikes and scooters tackle them in a sustainable, affordable, and convenient way.

At Atomico, as mobility continues to be disrupted, we are looking to back multiple solutions – especially if consumers love it and it is better for the city too. One of those areas is micro-mobility.

 

The ability to unlock, jump on and off Lime’s distinctive electric scooters anywhere is already delighting city-dwellers in over 70 locations across the US. In San Francisco, each of the company’s scooters is used an average of nine times a day.  It is clear the ‘form factor’ of the electric scooter is going to be a hit for shorter journeys where ride-hailing, public transport or even walking is not quite right.

The team has ambitious plans for European expansion, and we are proud to be their European investor as they scale to our continent. We’re joining the deal with other global investors GV, Andreessen Horowitz and Uber, whose excitement for Lime we share.

This is the ideal juncture for Atomico to partner with Lime. In the last decade, we’ve developed Atomico into a platform for sharing operational experience with our portfolio companies. We’re privileged to work with Brad and Toby, and excited to put our hard-won experience to work for Lime.

 

Categories: News

Tags:

KPN Ventures initiates Health Innovation Fund III, together with Menzis, Monuta and OostNL

 

After two previous successful funds, the third Health Innovations venture capital fund has been initiated to support innovative healthcare start-ups in developing their products and bringing them to the market. In the coming years, the fund will invest € 15 million in 10 to 15 starting tech companies. The fund is focused on innovative digital health solutions that keep healthcare affordable and improve the quality and accessibility of care.

Investors include KPN Ventures, Menzis, Monuta, Topfonds Gelderland, Oost NL and several private investors. The fund is further supported by the Ministries of Health and Economic Affairs. Together, they are investing 6 million euros from the Netherlands Enterprise Agency’s Seed Capital Scheme.

The investors will be contributing their expertise and networks to the fund and the health start-ups in order to increase their chances of success.

Focus on innovation in healthcare

The Health Innovation Fund III will invest in companies that have developed new products to make healthcare smarter, better and more accessible. These can be software, hardware and service solutions, as long as they are directed towards prevention, diagnosis, treatment or cure or care monitoring. Joris van Eijck, Director Healthcare at Menzis, emphasizes the importance of innovation in healthcare:

“The application of new technology means, for example, that patients can live at home longer or receive care in their familiar environment, rather than in the hospital. Technology gives healthcare a fundamentally different form and creates value for patients.”

This third Health Innovation fund will also explicitly target e-Health solutions that foster self-management, self-monitoring and self-reliance. The first two funds have already made 18 investments in promising companies, including Prolira, LivAssured, Nightbalance, ANW Nederland, Noviosense and Aidence.

According to the partners involved, innovation is not only required for keeping healthcare affordable, but can also further improve the quality of healthcare. As important stakeholders in the sector, they want to accelerate this process. That’s why, in addition to making resources available, they will also utilize their expertise and network to support the start-up enterprises. Herman Kienhuis from KPN Ventures confirms this: “Digital technology offers enormous opportunities to improve the quality and affordability of healthcare and to increase people’s self-reliance, also in the case of illness and old age. KPN wants to take on an important role in this field and seeks out and supports young tech companies to jointly develop innovations, also through its partnership with the Health Innovation Fund III.”

Organization

The Health Innovation Fund III is managed by Utrecht-based Health Innovations. The fund is supported by the Ministry of Economic Affairs, Agriculture and Climate and by the Ministry of Health, Welfare and Sport. In December 2017, the Netherlands Enterprise Agency selected the fund for its SEED Capital arrangement by means of a tender process. Secretary of State Keijzer from Economic Affairs and Climate, responsible for financing: “The production of new medical devices, for example for making diagnoses or for carrying out complex medical analyses, is good for the quality of healthcare and for our economic development. Investing in e-Health benefits us all and especially the people who need this care. With the SEED Capital scheme, we are supporting innovative entrepreneurs who can develop these ideas.”

Categories: News

Tags:

UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders

UCB Ventures

Syndesi Therapeutics to leverage UCB’s expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism • Series A financing of €17 M from a syndicate of Belgian and international investors

Brussels, Belgium – February 1st, 2018 – The creation of Syndesi Therapeutics (‘Syndesi’) was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors. The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund (SRIW) and VIVES Louvain Technology Fund. Syndesi Therapeutics has exclusively licensed a first-in-class small molecule program from UCB and the series A investment totalling €17M will fund the clinical development of the lead compound up to early proof-of-concept in humans.

Syndesi Therapeutics is based in Belgium and will leverage UCB’s neurology expertise in modulating the synaptic vesicle protein SV2A. UCB’s Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Unlike levetiracetam and other types of SV2A modulators discovered and developed by UCB for epilepsy, the novel compounds are devoid of anti-epileptic properties but have demonstrated robust pro-cognitive properties in preclinical models. Cognitive impairment currently being outside UCB’s strategic scope, the decision was made to have the program further developed externally to leverage its full potential. The discovery of these novel pro-cognitive SV2A modulators at UCB has benefitted from prior support of the Walloon Region, and Syndesi will use the Series A investment to build upon that work and move the lead molecule into clinical development.

“UCB is the world leader in SV2A research, having discovered and developed two major antiepileptic drugs treating patients around the world. We are excited to see Syndesi develop our novel pro-cognitive SV2A modulators to create value for patients with cognitive impairment,” said Dhavalkumar Patel, UCB’s Chief Scientific Officer and Executive Vice President. “The Belgian life science ecosystem is particularly vibrant and we realised that it was the right environment to promote this research as part of our biotech model approach.

” Jonathan Savidge, PhD CEO of Syndesi noted “Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimer’s Disease and other indications characterized by cognitive impairment. Syndesi benefits both from UCB’s research expertise and from an impressive syndicate of experienced investors and their respective networks.” “Cognitive impairment remains an area of significant unmet need for patients not only with Alzheimer’s Disease but also more broadly across a range of neurological disorders, and we are excited about the potential promise of this novel therapeutic approach,” says Morten Graugaard Døssing, Principal at Novo Seeds. “I am thrilled to be working with the company which is supported by scientists at UCB and able to leverage Janssen neuroscience expertise via a presence at the JLINX incubator, all in an effort to develop products that could one day make a meaningful difference for patients suffering from cognitive impairment.”

About Syndesi Therapeutics Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre d’Entreprises et d’Innovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. Syndesi has an exclusive, worldwide license from UCB to develop and commercialise a series of novel, pro-cognitive SV2A modulators. Syndesi will build on a rich legacy of work by UCB to further develop these novel SV2A modulators to investigate their potential to improve cognition in diseases such as Alzheimer’s Disease, other dementias and cognitive impairment associated with schizophrenia.

About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7500 people in approximately 40 countries, the company generated revenue of €4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

About Novo Holdings and Novo Seeds Novo Seeds is the early-stage investment arm of Novo Holdings (www.novoholdings.dk). Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. The company is the holding company in the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation’s assets. In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets.

About Fountain Healthcare Partners Fountain Healthcare Partners (www.fh-partners.com) is a life science focused venture capital fund with €176 million ($200 million) under management. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. The firm deploys the majority of its capital in Europe, with the balance in the United States. Fountain’s main office is in Dublin, Ireland, with a second office in New York.

About Johnson & Johnson Innovation – JJDC, Inc. (JJDC) Johnson & Johnson Innovation – JJDC Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to global healthcare entrepreneurs. Founded in 1973, JJDC continues a legacy of customizing deals for data-driven companies across the continuum of healthcare, with the goal of turning great ideas into transformative new pharmaceutical, medical device and consumer healthcare products. www.jjdc.com

About V-Bio Ventures V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world’s premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.

About SRIW SA SRIW Société Régionale d’Investissement de Wallonie (www.sriw.be) provides equity and/or debt to companies that generate added value and employment in Wallonia. SRIW facilitates the region’s economic development, contributing effectively to the modernisation, growth and restructuring of the businesses that make up the Walloon industrial network. In the life science sector, SRIW is investor in more than 30 companies such as I.B.A., Celyad, or Ogeda of which it recently exited. Its current portfolio fair value is above 150 million €. About VIVES-Louvain Technology Fund The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Université catholique de Louvain (UCL) and startups in Belgium and neighboring countries. VIVES II is funded by a dozen leading Belgian and European investors such as the EUROPEAN INVESTMENT FUND (EIF), SFPI-FPIM, BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM, BPI FRANCE (France), ING BELGIUM, SOFINA, AXA BELGIUM, BELFIUS, IRD (France), NIVELINVEST, REGION BRUXELLES CAPITAL and by SOPARTEC. The objective of the fund is to invest in the development of start-ups, from validation of the technology to commercial maturity. The funds (VIVES I – €15 million and VIVES II – €43 million) are managed by SOPARTEC, UCL’s technology transfer company, member of the Louvain Technology Transfer Office.

For further information, UCB: Corporate Communications France Nivelle Global Communications, UCB T +32.2.559.9178 france.nivelle@ucb.com Laurent Schots Media Relations, UCB T+32.2.559.92.64 Laurent.schots@ucb.com Investor Relations Antje Witte Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com

UCB Forward-Looking Statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Open PDF of “Syndesi Therapeutics ENG” Open PDF of “Syndesi Therapeutics FR” Open PDF of “Syndesi Therapeutics NL”

Categories: News

Tags:

Mytonomy Announces Series A Financing Headlined by an Investment from Philips

Philips Ventures

Bethesda, Maryland –November 29, 2017 – Mytonomy, a leader in provider driven patient experience solutions to improve patient outcomes, announced it is closing a $7M Series-A funding round, including an investment from Philips, a global leader in health technology.

“Philips brings an extensive track record in consumer health and professional healthcare in key areas that align with Mytonomy’s growth, such as cardiology, oncology, imaging, mother/child care and population health. Philips is a value-add investor as we scale our Patient Experience Cloud business. We are thrilled to have members of the Philips Health Technology Ventures team join our board as they bring decades of healthcare industry and software execution expertise,” said Anjali Kataria, CEO of Mytonomy.

“Mytonomy’s software platform drives multiple benefits for many stakeholders in the provider environment, simultaneously; we drive longitudinal patient activation, improve patient, family and staff satisfaction, decrease labor costs, and increase top-line growth by delivering a significantly better, data-driven, personalized patient experience across the entire care continuum,” said Kataria.

“The results that Mytonomy and its founders have achieved in recent years are very impressive,” said Rich Wilmot, head of Philips Health Technology Ventures. “Their innovative product has strong traction in the market as hospitals achieve very high patient satisfaction from patients who use Mytonomy’s cloud-based patient education system. Moreover, Philips and Mytonomy share a joint vision of marrying unique data sets such as patient-reported outcomes and clinical metrics to drive better clinical outcomes, while enhancing the patient experience, and driving down inefficiencies and cost. We look forward to teaming up with Mytonomy to help grow the business, and ultimately forge a productive partnership path for the two companies.”

Other notable investors include MedStar Health and Super Angels such as George John, co-founder of Rocket Fuel and an AI thought leader, and Gokul Rajaram, Head of Product for Square and a former Facebook and Google executive.

Mytonomy seamlessly spans pre-procedure, pre-arrival, in-patient, discharge, at home, and ambulatory care with a consumer like experience that is both high-tech and high-touch increasing labor efficiency of staff. “Nurses call Mytonomy their virtual assistant,” said Kataria.

“Like popular consumer video streaming services, Mytonomy delivers personalized content directly to patients on any device throughout their care journey,” said Vinay Bhargava, Mytonomy’s Co-founder and President. “Bringing user-centric design principles to healthcare has led to very high patient usage across all major demographics and is delivering a fantastic, tailored patient experience for each patient,” he said.

The patient experience is of paramount importance to the healthcare industry.  Gartner’s 2017 report “The Future of Experience in Healthcare Demands a Consumer-Aligned Collaborative Ecosystem”*, includes the following observations:

  • Sixty-one percent of U.S. integrated delivery systems (IDSs) now have a senior executive specifically charged with accountability for the patient experience.
  • The experiences that consumers have in healthcare — positive or negative — influence their future decisions when navigating the healthcare system and their personal health behaviors. These decisions are powerful determinants of health outcomes and medical costs.

 

*Gartner, “The Future of Experience in Healthcare Demands a Consumer-Aligned Collaborative Ecosystem,” Jeff Cribbs, Mark E. Gilbert, 28 April 2017.

About Mytonomy

Mytonomy is the leader in Patient Experience Cloud Software for hospitals and providers. Leveraging behavior science, Mytonomy offers a data driven personalized patient education, engagement and experience software platform resulting in unprecedented cost savings and improvements in patient outcomes. Our cloud software combined with modern microlearning video education enables seamless access across the care continuum:  pre-procedure, pre-arrival, in-patient, discharge, at home, rehabilitation and ambulatory care with a consumer like experience, that is both high-tech and high-touch.  Mytonomy’s founders are former executives from Google, Oracle, and the FDA.  The company is headquartered in Bethesda, MD. For more information, visit www.mytonomy.com.

Categories: News

Tags:

Medical Artificial Intelligence company Quantib receives capital injection of EUR 4.5 million

Faster and more objective diagnoses by automatic interpretation of MRI and CT scan data

Chicago, 27 November 2017 – At the world’s largest radiology conference (RSNA), medical Artificial Intelligence (AI) company Quantib announced today that it secured €4.5mln ($ 5.4mln) of fresh funding in a round that was led by Holland Venture and InnovationQuarter. Quantib develops Machine Learning (ML) applications for medical imaging analyses, allowing physicians and researchers to make more efficient and more accurate diagnoses. The investment supports Quantib with her international scale-up ambitions.

Founded in 2012 and headquartered in Rotterdam, The Netherlands, Quantib is one of the most renowned Dutch players in the field of medical AI applications. Quantib utilizes ML software for the segmentation, classification and quantification of medical images, improving diagnostic quality and allowing for a more efficient workflow of physicians and researchers. Quantib is a spin-off of the Erasmus MC, developing her products in close collaboration with the internationally recognized Biomedical Imaging Group Rotterdam (BIGR) under supervision of Prof. dr. Wiro Niessen. Moreover, Quantib has strong partnerships with industry players (GE Healthcare, Philips and Intrasense) for research, development and the distribution of her products. Recently, Quantib received media coverage as winner of The Dutch Data Science prize . Quantib’s first products received FDA approval and CE marking in 2016 and focus on the detection and tracking of neurological disorders such as Parkinson, Multiple Sclerosis and Alzheimer’s disease.

The investment allows Quantib to bring new ML applications to the market with regards to stroke, lung disorders, oncology and bone structures. Quantib will also establish new partnerships with leading international academic hospitals.

In conjunction with the investment, the management team has been reinforced with Arthur Post Uiterweer (former Philips and Boston Consulting Group) and Jorrit Glastra (former Shell). The supervisory board will consist of Prof. dr. Gabriel Krestin, Harm-Jan Wessels and health entrepreneur Jaap Maljers.

Rudolf Scholte, CEO of Quantib: “Our software supports radiologists and neurologists with their objective assessment of MRI- and CT scans. Our deep learning algorithms can support better diagnoses, and a better assessment of treatments’ effectiveness. Up until now, our main focus was on brain disorders. This investment allows us to develop new products and to extend our team.”

“Quantib’s applications help standardise and speed up image analysis and allows for the detection of subtle changes over time. It increases the objectivity of the diagnostic process and therefore delivers an improved diagnosis combined with more efficient processes, positively impacting a large group of patients. We see large international growth opportunities for the company and we are proud to be a part of this development.” says Ewout Prins, Managing Partner Holland Venture.

Francis Quint, Head InnovationQuarter Capital: “Quantib facilitates faster, better and more efficient diagnoses, a fantastic result from the close collaboration with Erasmus MC. We are happy to support this Rotterdam-based company with their ambition to extend the range of their current technology to other applications.”

Categories: News

Tags:

Divergent 3D Announces Series B and Related Funding

Horizons Ventures

LOS ANGELES and HONG KONG— November 21, 2017— Divergent 3D, a technology development and licensing company that is creating a sustainable manufacturing revolution in the car industry, announces a Series B financing scheduled for close on or before December 15, 2017. The Series B close is $65+million with an additional investor option of $40 million to further accelerate revenue growth, bringing the aggregate funding, with option, to $107 million. Hong Kong-based investment holding company, O Luxe Holdings Limited (“O Luxe”), led the investment group, which includes Horizons Ventures, Shanghai Alliance Investment Limited and Altran Technologies.

Launched in 2014 by Founder & CEO Kevin Czinger, Divergent’s patented, end-to-end software-hardware solution incorporates 3D metal printing into the design, engineering and manufacturing of advanced vehicle structures for the automotive and aerospace industries. Its proprietary Divergent Production System™ automates structural design and optimization for volume manufacturing of lightweight structures without upfront, capital-intensive factory and tooling investments.

“With the ability to quickly respond to market demands, the Divergent system allows automakers and technology companies to innovate at a much faster rate—scaling up volume production at only a fraction of the cost while also alleviating environmental damage,” explains Czinger. “As a leading investment holding company dedicated to advancing sustainable manufacturing and transportation, O Luxe aligns with Divergent’s mission and fully understands the importance of disruptive technologies to the automotive industry. We are thrilled to partner with a company that supports our growth and vision.”

Marking a major financial milestone, the Series B funding will accelerate the commercialization of Divergent’s technology and provide additional resources to proliferate the technology globally, especially in the rapidly expanding Chinese electric vehicle market. Through non-exclusive partnerships with automakers and technology companies, Divergent will continue its strong momentum in leading the adoption of an economically and environmentally transformative manufacturing solution—building safer, stronger and more profitable eco-friendly vehicles at mass volumes.

In January 2016, Divergent announced the first close of its Series A financing and received a total of $23 million Series A funding. Since then, the technology development and licensing company has received global recognition for its manufacturing solution, and forged strategic partnerships with Altran, SLM Solutions and PSA Group (Peugeot, Citroen & DS).

 

About Divergent 3D

Divergent 3D harnesses the power of 3D printing to unleash innovation in automotive manufacturing. Its breakthrough technology platform transforms the economics and environmental impact of designing and manufacturing complex structures such as cars. Divergent’s planet-saving manufacturing approach enables both low and high volume manufacturing without costly, traditional tooling and capital expenses, enabling manufacturers to quickly iterate and invent new vehicle models for competitive advantage. As a technology company, Divergent partners with OEMs and innovative startups around the world to produce the next generation of vehicles. For more information, please visit www.divergent3d.com.

 

About O Luxe Holdings

O Luxe Holdings Limited is a Hong Kong-based investment holding company focused on developing technology-based companies that will accelerate the global adoption of electric vehicles and drive the world toward sustainable manufacturing and transportation. O Luxe company most recently acquired GLM Co., Ltd, a Japanese electric vehicles and engineering solutions company, and received a major investment from Mr. Li Ka-shing, a renowned Hong Kong entrepreneur, investor, and philanthropist. The Group is principally engaged in distribution of watches, wholesale trading of jewellery products, mining, money lending and securities investments.

 

About Horizons Ventures

Horizons Ventures, the private investment arm of Mr. Li Ka-shing, is a leading investor in some of the world’s most innovative companies and disruptive technologies, including Facebook, Spotify, Impossible Foods, Improbable, Zoom, Blockstream, Soul Machines and ChromaDex. For more information, please visit http://horizonsventures.com/

 

About SAIL

Shanghai Alliance Investment Limited is a private equity and venture capital arm of Shanghai Municipal Government. The firm invests in high-tech, media, entertainment, infrastructure, financial services, telecommunication, healthcare, life science, and emerging low-carbon sectors such as clean energy, new material and eco-environment protection. Shanghai Alliance Investment Ltd. was founded in 1994 and is based in Shanghai, China.

 

About Altran

As a global leader in Engineering and R&D services (ER&D), Altran offers its clients a new way to innovate by developing the products and services of tomorrow. Altran works alongside its clients on every link in the value chain of their project, from conception to industrialization. For over thirty years, the Group has provided its expertise to key players in the Aerospace, Automotive, Defense, Energy, Finance, Life Sciences, Railway, and Telecoms sectors, among others. With a headcount of more than 27,000 employees, Altran has a presence in more than 20 countries.

 

 

Media Contact

Lydia You | ID-PR

divergent@id-pr.com

(323) 822.4849

Categories: News

Tags:

Axel Bard Bringéus joins EQT Ventures

EQT Ventures

EQT Ventures has strengthened its team of investment specialists and operational experts with Axel Bard Bringéus, former Global Head of Markets at Spotify, joining the fund. Get to know Axel in this video and find out how he will help to identify fast-growing, innovative and tech-enabled companies for support and investment in Germany.

Categories: People

Tags:

Roche Acquires Lab Data Analytics Platform Viewics

Canvas Ventures

Roche Acquires Lab Data Analytics Platform Viewics

Roche, a pharmaceuticals and diagnostics focused on advancing science has announced an agreement to acquire Viewics, Inc., a laboratory business analytics platform. Under the terms of the agreement, Roche is acquiring all shares of the company. Financial details of the acquisition were not disclosed.

As part of the acquisition, Viewics, Inc. will become an integral part of Roche and add further digital capabilities on top of Roche Diagnostics’ Integrated Core Lab offering to make faster data-driven informed decisions on their operations and processes.  The cloud-based solution is secure, infrastructure-agnostic, interactive, and accessible from multiple devices (e.g. smart phones, tablets, desktop computers).

Founded in 2010 in Sunnyvale, CA, the Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond, pioneering a new way in extracting, cleansing, transforming and augmenting data. The HIPAA-compliant solution puts the transformational power of analytics into the hands of healthcare professionals in laboratory, financial, executive, and IT roles.

The solution enables organizations to leverage insights out-of-the-box, combined with the flexibility of further customising the solution to meet the needs of their unique situations, truly interact with their data and make decisions based on accurate information to deliver significant impact.

Categories: News

Tags:

Investment update: Zego raises £6M Series A to provide gig economy worker insurance

Balderton

We’re very excited to see Clerkenwell, London-based pay-as-you go insurance provider Zego announcing their £6m in series A funding today, led by Balderton and joined by original investor Local Globe and angel investors in the insurance sector. Rob Moffat will be taking a seat on the Zego board.

Zego is preparing to launch new products specially designed for flexible workers employed in the sharing economy.

Zego co-founders Harry, Sten and Stuart

Zego was founded by former Deliveroo managers last year, and the team has grown from seven to 33 employees since the start of 2017. They’re planning to use the funding to hire more specialists for their engineering team, as well as staff to build key business functions.

Read coverage of the announcement on Techcrunch here.

Categories: News

Tags:

Insight Venture Partners Invests $26M Series B in LeanTaaS to Fuel Growth of Healthcare Operations Platform

Insight Venture

SANTA CLARA, Calif.–LeanTaaS, Inc., a Silicon Valley software innovator that increases patient access and transforms operational performance for healthcare providers, today announced that new investor Insight Venture Partners, a leading global venture capital and private equity firm, has invested $26 million in a Series B round of financing.

“Healthcare is a difficult space in which to bring about radical change,” said Jeff Horing, co-founder and managing director of Insight Venture Partners. “We are impressed by the quality of deep customer partnerships, the product portfolio and the team that LeanTaaS has assembled.”

The company’s solutions — relied upon by more than 40 of the nation’s leading hospitals and infusion centers — use lean principles, predictive analytics, machine learning and the cloud to dramatically improve the patient experience. LeanTaaS customers have reduced wait times for appointments and surgeries by up to 50 percent, increased patient access by as much as 30 percent and improved operational performance up to 20 percent through increased revenue and reduced costs.

The mathematical foundation on which patient appointments are scheduled is fundamentally flawed. As a result, expensive assets like infusion chairs, operating rooms, diagnostic imaging equipment and inpatient beds are commonly over- and underutilized, often on the same day.

LeanTaaS has quickly emerged as the leader in using advanced data science and mathematics to address this perplexing paradox. The company’s patent-pending algorithms help providers do more with existing assets and defer investments in additional staff, equipment and facilities. LeanTaaS solutions also improve surgeon access to valuable operating room time, lower wait times for patients and level-load the day for anesthesiologists, nurses and staff.

“We are privileged to work with many of the leading health systems in the country to demonstrate the impact of combining lean principles, predictive analytics and scalable software to drive significant improvements in operational performance and asset utilization,” said Mohan Giridharadas, founder and CEO of LeanTaaS. “This investment from Insight Venture Partners is a strong validation of our approach and will enable us to dramatically accelerate our growth over the coming years.”

The financing will fund continued investment in the LeanTaaS iQueue platform, which currently consists of two solutions: iQueue for Infusion Centers and iQueue for Operating Rooms. In May 2017, the company also established iQueue Labs, which explores answers to emerging, significant operational challenges in diagnostic imaging departments, emergency departments, pharmacies, labs and inpatient beds. The iQueue platform is a cloud service that works with any electronic health record and requires only minimal assistance by the provider’s internal IT staff to set up and use.

LeanTaaS joins an Insight Venture Partners portfolio that already boasts five companies on Inc.’s annual ranking of the fastest-growing private companies in America.

Categories: News

Tags: